Aberdeen based biotech firm have been nominated for the Most Innovative European Biotech SME award. NovaBiotics have developed new treatments to tackle infections, including MRSA, which are proving increasingly resistant to existing antibiotics. Over the past 13 years the company has raised £20million to finance the business and secured hundreds of patients. They believe they have made a breakthrough which will show significant results in the...
Professor Karen Faulds has been named amongst the top 10 leading scientists in her field in an international survey conducted by Analytical Scientists magazine. Professor Faulds specialises in the spectroscopic technique known as SERS, in which she explores new approaches to bioanalysis for use in life and clinical sciences. SERS has the ability to obtain a large amount of information in a single measurement, allowing...
Gemini Therapeutics, received $42.5 million through a Series A funding round to develop their research in dry age-related macular degeneration (Dry AMD), a common cause of sight loss. Co-funded by Biochemists Paul Barlow and Andy Herbert alongside biotechnology entrepreneur James McLaughlin, the Massachusetts based company is advancing the development in partnerships and exclusive technology transfers whilst developing technology that will determine the role of the bodies immune...
Leishmania is a parasite that infects 1 million people each year causing 20,000-30,000 deaths. Researcher’s from the University of Edinburgh have made a discovery that has improved scientists understanding of how the parasite functions and as a result how to target the infectious parasite. The Leishmania parasite tends to be found in the tropics and subtropics of Europe and is transmitted through infected sandflies. The...
Results from the IMPROVE-COLPO study were announced showing the outcome of using the DYSIS Colposcope in community based colposcopy clinics in the USA. The study examined more than 7,500 women in 47 clinics making it that largest colposcopy study ever undertaken. The results showed that there was a significant increase in the detection of women with precancerous lesions among those examined with the DYSIS Colposcopy...
TC BioPharm have joined forces with University College London to develop treatment for Leukaemia. The agreement aims to progress UCL’s gene-modified T cell therapies that are capable of treating cancers of the blood. To read the full article, click here.